Medicine
Stories from Medicine come first, newest first, then stories from connected topics (AI Science & Health, Healthcare, Hub: Tech for Good, healthcare AI, Biotech, drug discovery), each labelled with where it comes from. This view is not indexed by search engines.
Nature Cancer Publishes THREADS Pathology Foundation Model
Mass General Brigham’s THREADS pathology model is published in Nature Cancer after a Jan 2025 preprint. It is a research result, not a clinical product.
Latest
Lupus Patients’ Immune Cells Target Proteins Made by Splicing Errors
Lupus neoantigens made by faulty mRNA splicing in neutrophils drew T and B cell responses, a Nature study finds. Trials must test if they drive disease.
26% of Fetal Neurons Carry Big DNA Errors, Falling to 6% After Birth
A Nature study of 2,357 brain cells finds about a quarter of fetal neurons carry widespread DNA copy changes, falling to about 6% after birth.
AI Screened 6,680 Molecules and Helped Find a New Antibiotic, Abaucin
An AI model ranked 6,680 compounds in under two hours and helped find abaucin, which treated superbug infections in mice. It isn't a medicine yet.
AI-Edited Antibody Bound IL-6 13 Times More Tightly in Lab Tests
AbOptimizer edited three therapeutic antibodies with an AI model and reinforcement learning. One bound IL-6 13 times more tightly, in lab tests only.
3D-Printed Holograms Steer Ultrasound to Stroke Damage in Mice
ShanghaiTech researchers used 3D-printed acoustic holograms and one ultrasound transducer to deliver stem-cell therapy around stroke damage in male mice.
KRAS Pancreatic Cancer Vaccine Misses Main Goal but Primes T Cells
An off-the-shelf KRAS vaccine missed its main goal in a 144-patient pancreatic cancer trial, but 89 of 90 evaluable patients mounted a T-cell response.
Early NIH-Led Trial Finds T-Cell Drug Invika Stalls Resistant Tumours
In an early trial led by NIH researchers, T-cell drug invika stopped cancer growing in 16 of 27 patients at the optimal dose and shrank tumours in four.
Personalised mRNA Therapy Cuts Melanoma Recurrence or Death Risk 42%
In a 1,137-patient phase 3 trial, intismeran plus Keytruda cut the risk of melanoma recurrence or death by 42%. Survival data are not yet mature.
The Drug Was Designed by an AI: How Insilico and Lilly Just Changed Medicine Forever
Something remarkable is happening in a lab you've never heard of, funded by a deal that barely made the news cycle. Last week, Eli Lilly — one...
AI Just Designed a Drug That Kills Superbugs Without Harming Good Bacteria
AI Just Designed a Drug That Kills Superbugs Without Harming Good Bacteria
MIT researchers used artificial intelligence to create NG1 — a precision antibiotic that...
Latest on TSN
Explore the TSN Atlas: Every topic we cover, mapped. Click a bubble to dive in.
